Camp4 Therapeutics (CAMP) Common Equity (2023 - 2026)
Camp4 Therapeutics (CAMP) posted Common Equity of $30.9 million for Q1 2026, down 35.22% sequentially from $47.7 million in Q4 2025, and down 40.08% YoY from $51.6 million in Q1 2025.
Camp4 Therapeutics (CAMP) Common Equity (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has reported Common Equity for 4 years, with the latest figure at $30.9 million in Q1 2026.
- Quarterly Common Equity fell 40.08% year-over-year to $30.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.9 million (down 40.08% YoY) and the FY2025 annual result came in at $47.7 million, down 24.45% from the prior year.
- Common Equity eased to $30.9 million in Q1 2026 per CAMP's latest filing, from $47.7 million in the prior quarter.
- Over five years, Common Equity peaked at $63.1 million in Q4 2024 and troughed at -$159.0 million in Q3 2024.
- A 4-year average of -$35.0 million and a median of $30.9 million in 2026 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 151.03% in 2024, down 42.51% in 2024.
- Over 4 years, Common Equity stood at -$123.7 million in 2023, then surged by 151.03% to $63.1 million in 2024, then fell by 24.45% to $47.7 million in 2025, then slumped by 35.22% to $30.9 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $30.9 million, $47.7 million, and $58.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - | -693,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -693,000.00 |
| Mar 31, 2026 | 30.90 Mn |
| Dec 31, 2025 | 47.70 Mn |
| Sep 30, 2025 | 58.67 Mn |
| Jun 30, 2025 | 39.99 Mn |
| Mar 31, 2025 | 51.57 Mn |
| Dec 31, 2024 | 63.14 Mn |
| Sep 30, 2024 | -158.98 Mn |
| Jun 30, 2024 | -147.11 Mn |
| Mar 31, 2024 | -135.33 Mn |
| Dec 31, 2023 | -123.73 Mn |
| Sep 30, 2023 | -111.55 Mn |